Bad Heilbrunn, Germany

Bianca Gruenwalder

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Bianca Gruenwalder: Innovator in Multispecific Antibody Analysis

Introduction

Bianca Gruenwalder is an accomplished inventor based in Bad Heilbrunn, Germany. With a focus on improving the analysis of multispecific antibodies, she has made a significant contribution to the field of biopharmaceuticals. Her innovative work has led to the development of a patented method that enhances the detection of antibody light chain mispairing.

Latest Patents

Bianca holds one patent, titled "Method for detecting multispecific antibody light chain mispairing." This invention outlines a technique that employs a limited digestion with a proteolytic enzyme to analyze the light chain pairing of multispecific antibodies. This method helps in the identification and characterization of antibody light chain mispairing, which is crucial for ensuring the efficacy and safety of therapeutic antibodies.

Career Highlights

Bianca is currently affiliated with Hoffmann-La Roche Inc., a leading global healthcare company specializing in pharmaceuticals and diagnostics. Her tenure at Hoffmann-La Roche has allowed her to engage in cutting-edge research and development, contributing to the advancement of antibody technologies.

Collaborations

Throughout her career, Bianca has collaborated with notable colleagues such as Michael Molhoj and Maximiliane Koenig. These collaborations have fostered innovation and enhanced the research landscape at Hoffmann-La Roche, underscoring the importance of teamwork in scientific endeavors.

Conclusion

Bianca Gruenwalder's work in the field of multispecific antibodies exemplifies the impact of innovation in biopharmaceutical research. Her patented method represents a significant advancement in the analysis of antibody light chain pairing, contributing to the development of safer and more effective therapeutic solutions. As she continues her work at Hoffmann-La Roche, Bianca remains a key figure in the ongoing evolution of antibody technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…